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Increasing evidence suggests that the misfolding and deposition of IAPP plays an important role in the pathogenesis of type II, or non-insulin-
dependent diabetes mellitus (T2DM). Membranes have been implicated in IAPP-dependent toxicity in several ways: Lipid membranes have been
shown to promote the misfolding and aggregation of IAPP. Thus, potentially toxic forms of IAPP can be generated when IAPP interacts with
cellular membranes. In addition, membranes have been implicated as the target of IAPP toxicity. IAPP has been shown to disrupt membrane
integrity and to permeabilize membranes. Since disruption of cellular membranes is highly toxic, such a mechanism has been suggested to explain
the observed IAPP toxicity. Here, we review IAPP–membrane interaction in the context of (1) catalyzing IAPP misfolding and (2) being a
potential origin of IAPP toxicity.
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It is estimated that nearly 20 million individuals in the United
States suffer from diabetes [1]. In addition to the debilitating
effects directly associated with diabetes, individuals who have
this disease are at a higher risk of developing stroke, hyper-⁎ Corresponding author. Tel.: +1 323 442 1323; fax: +1 323 442 4404.
E-mail address: langen@usc.edu (R. Langen).
0005-2736/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2007.01.022tension and heart disease [2,3]. The vast majority of diabetics,
almost 90%, suffer from type II, or non-insulin-dependent
diabetes mellitus (T2DM). Thus, this form of the disease
represents a significant health problem. Pancreatic deposits are
a common pathophysiological feature of T2DM, and are found
in over 90% of all cases, mainly as extracellular deposits near
the insulin-producing beta cells [4,5]. Although the presence of
pancreatic deposits in T2DMwas identified more than a century
ago [6], their classification as amyloids did not occur until more
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dently identified the 37-residue islet amyloid polypeptide
(IAPP, also known as amylin) as the major component of
pancreatic amyloid [8,9]. IAPP is synthesized in pancreatic β-
cells and is co-secreted with insulin in response to glucose or
non-glucose stimulants [10,11]. Although the physiological
functions of IAPP are still not well established, it has been
shown that the peptide affects a variety of processes, including
carbohydrate metabolism, modulation of insulin secretion,
inhibition of bone resorption, suppression of gastric emptying,
and food intake [12–16].
Increasing evidence suggests the importance of IAPP
misfolding and amyloid fibril formation in the pathogenesis
of T2DM. IAPP misfolding and fibril formation generates
species that are toxic, when added exogenously, to cultured
human islets and β-cells [17–19]. In addition, over-expression
of IAPP in COS cells leads to the intracellular misfolding and
accumulation of IAPP aggregates, and eventually to cell death
[20,21]. IAPP in humans, monkeys and cats is amyloidogenic
and these species are known to develop T2DM. In contrast, rats
and mice do not develop T2DM, since rat and mouse IAPP's are
non-amyloidogenic and appear not to be toxic to cultured cells
[22]. Importantly, transgenic mice and rats that express human
IAPP (hIAPP) develop fibrillar deposits and exhibit signs of
diabetes (e.g., hyperglycemia) [23,24]. Furthermore, it has been
shown that transgenic rodents expressing hIAPP are at
increased risk of becoming diabetic in a background of obesity
(a major risk factor for T2DM) [25–27]. These symptoms seem
to be brought about by the presence of misfolded hIAPP, which
results in a loss of β-cell mass and, ultimately, leads to
insufficient insulin secretion [24,28]. It is thought that such β-
cell loss, together with insulin resistance, participates in the
pathogenesis of T2DM in humans. Further support for the role
of hIAPP in disease comes from the discovery that the S20G
mutation in hIAPP has been linked to a familial form of early
onset T2DM [29]. It has been found that this mutation is
significantly more cytotoxic than the wild-type peptide and that
it aggregates more rapidly [30,31]. Taken together, these studies
suggest a causal relationship between the deposition of hIAPP
amyloid, β-cell loss and T2DM.
hIAPP forms amyloid fibrils with characteristics similar to
those of other amyloid proteins. Like other amyloid proteins,
hIAPP forms fibrils that have a significant β-sheet content
[32–34]; X-ray diffraction studies have shown that these β-
sheets are arranged in a cross β-configuration within the fibril
[35]. Our own electron paramagnetic resonance studies, together
with site-directed spin labeling, have shown that the fibrillar core
of hIAPP is highly ordered and that the individual β-strands are
arranged in a parallel fashion [36]. These are features that hIAPP
fibrils share with those of Alzheimer's Aβ peptide (Alzheimer's
disease), α-synuclein (Parkinson's disease), tau (Alzheimer's
disease), and a fragment of the yeast prion [37–41].
In addition to these structural similarities, a growing body of
evidence suggests that amyloid fibrils from different proteins
and peptides, including hIAPP, may form by similar molecular
mechanisms. Fibril formation is a multi-step process in which
the formation of smaller oligomeric protein structures precedesthe formation of mature fibrils [42]. Although there is still
debate as to whether oligomers, mature fibrils, or some other
“off-pathway oligomers” are responsible for toxicity, accumu-
lating experimental evidence suggests that a non-fibrillar
oligomeric species (sometimes also referred to as protofibrils,
micelles or ADDLs) plays an important role in cellular toxicity
[42]. Some of the first evidence that non-fibrillar oligomers,
rather than the mature fibrils of hIAPP, might be responsible for
toxicity came from studies of transgenic mice that expressed
hIAPP. In these mice, pathological changes were observed prior
to the formation of pancreatic amyloid deposits [23]. Further-
more, non-fibrillar oligomers were found to be significantly
more toxic to islet cells than were the mature fibrils [17]. A toxic
species other than mature fibrils may also serve to explain the
poor correlation observed between the amount of hIAPP
amyloid deposition and β-cell degeneration [20,23]. A recent
report describes the isolation of an antibody with conforma-
tional specificity to the toxic oligomeric species from
Alzheimer's Aβ peptide [43]. Interestingly, this antibody was
also able to recognize toxic oligomeric species from hIAPP as
well as a number of other amyloid proteins, and was found
capable of preventing their toxic effects. Such observations
suggest that oligomers from different amyloidogenic proteins
share common structural features, and that similarities may also
exist with respect to their mechanisms of toxicity and even their
formation.
2. IAPP membrane interactions
The similarities between hIAPP and other amyloidogenic
proteins also extend to their ability to interact with lipid
membranes, and several recent reports have shown that such
protein–lipid interactions may play an important role in the
pathogenesis of amyloid disease [17,44–56]. Membranes have
been implicated both as the targets of oligomer toxicity, via
disruption of membrane integrity [17,53–55] and as the catalyst
that facilitates oligomer formation [48–52].
Given the likelihood that the formation of aberrant protein
conformations plays an important role in T2DM and other
amyloid diseases, elucidating the molecular mechanisms of
hIAPP aggregation has been receiving increasing attention.
Here, we review our current molecular understanding of hIAPP
membrane interaction, including membrane-mediated aggrega-
tion of hIAPP as well as its ability to disrupt membrane
integrity.
2.1. Membrane-mediated aggregation of IAPP
2.1.1. Effect of lipid composition
It has been well established that lipid membranes can
promote the aggregation of hIAPP [48,57–59]. Lipid composi-
tion appears to be one of the primary factors that determine the
extent to which membranes promote hIAPP aggregation.
Particularly strong enhancement of hIAPP aggregation has
been observed in the presence of membranes that contain
negatively charged lipids, such as phosphotidylglycerol (PG) or
phosphatidylserine (PS) [48,58]. In the presence of such
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opposed to the several hours (or days) it takes when membranes
are absent [48,58]. It is thought that electrostatic interactions
between negatively charged lipids and the positively charged
hIAPP play an important role in membrane-mediated aggrega-
tion. Depending on pH, hIAPP can carry up to four positive
charges (a free N-terminal charge, K1, R11, and H18, see Fig.
1). The notion that electrostatic interactions are important is
further supported by the fact that membrane-mediated aggrega-
tion of hIAPP is strongly modulated by ionic strength [48,58] as
well as by mutations, either through deletion of the lysine at
position 1 or through the use of peptides that lack the first seven
residues, thus affecting the N-terminal positive charges [48].
Although the strongest enhancement of hIAPP aggregation
was obtained for membranes with relatively high contents of
negatively charged lipid, significant acceleration (between a
two- and ten-fold increase in kinetics) was also observed at
more physiological concentrations of 1–10 mol% PS [58]. This
concentration range is within the 4–14% PS content reported for
membranes from the pancreatic islets of rodents [60]. Thus, the
charge density of these cellular membranes is certainly high
enough to significantly increase hIAPP aggregation. The
precise effect of cellular membranes, however, will depend on
the location of hIAPP and the exact lipid composition of a given
cell (which can vary depending on the state of a cell). Typically,
PS is highly enriched on the cytosolic face of the plasma
membrane and is less concentrated on the extracellular surface
[61]. hIAPP could have access to both of these sides, as it is not
only a secreted peptide, but has also been detected within the
cytoplasm, where it was found to aggregate [20,23,62]. Thus,
intra- as well as extracellular membrane-mediated aggregation
could be of physiological relevance. Interestingly, it has also
been found that IAPP aggregation was influenced by free fatty
acids in cultured islet cells in vitro [63].
2.1.2. Mechanism of membrane-mediated aggregation
The precise molecular mechanisms by which membranes
catalyze the aggregation of hIAPP are not yet fully understood,
as high-resolution structural information of this process is stillFig. 1. Primary structure and sequence characteristics of islet amyloid polypeptide (IA
amine N-terminus. Rat IAPP (rIAPP) differs from the human peptide (hIAPP) by six r
29. (A) Helical regions observed for calcitonin and the calcitonin gene-related pep
residues 8 and 18. Calcitonin and CGRP belong to the same superfamily as IAPP. (
between residues 20 and 29. (C) Analysis of amphipathicity indicates that the most
extend between residues 10 and 27. (D) Residues with high helical propensity [93] on
found on the C-terminal end of the peptide.lacking. Nonetheless, some structural details have been
elucidated using low-resolution structural tools, such as circular
dichroism (CD) and fluorescence spectroscopy [48,57,58] (see
Fig. 2). In solution, hIAPP adopts a predominantly random coil
structure [34,58] with only small components of β-sheet/β-turn
and α-helical conformations [34]. In contrast, the CD spectra of
aggregated and fibrillar hIAPP are indicative of a predominantly
β-sheet conformation [34]. Our CD studies have indicated that
membrane-mediated oligomerization of hIAPP proceeds via a
previously unidentified α-helical conformation [58]. This
membrane-bound, α-helical conformation is transient in nature
and disappears at the same rate at which thioflavin-positive β-
sheet structures appear [57,58]. According to electron micro-
graphs, the resulting β-sheet structures contain mature fibrils
with a morphology similar to that of fibrils formed in the
absence of lipid. In addition, smaller, non-fibrillar oligomeric
structures were also observed [58].
The induction of an ordered, typically α-helical structure is
commonly observed for many membrane-interacting polypep-
tides, including the classical example of bee venom melittin
[64]. The formation of secondary structure is thought to result
from the need to hydrogen-bond the peptide backbone when it
partitions to the membrane, where the dielectric constant is
significantly lower than it is in solution [65,66]. In the case of
hIAPP, CD data reveal that about half of the residues (∼15–20
amino acids) are incorporated into an α-helical structure upon
interaction with either PS- [58] or PG-containing membranes
[57]. Importantly, the remainder of the peptide is unfolded
despite its proximity to the low dielectric environment of the
membrane. This low-resolution structural information already
suggests two molecular mechanisms that are likely to contribute
to the membrane-mediated aggregation of hIAPP. (1) A
significant driving force should exist to favor the secondary
structural formation of residues that remain unfolded in the
membrane-bound environment [67]. Such secondary structure
formation would include the formation of an intermolecular
β-sheet structure in hIAPP (also see below). (2) Furthermore,
the formation of β-sheet oligomers and fibrils would also be
promoted by the increased local concentration of the peptidesPP). The 37-residue peptide contains a conserved amidated C-terminus and a free
esidues, with the most significant differences occurring between residues 23 and
tide (CGRP) in membranes/membrane mimetic environments extend between
B) The most significant inter-species variations in the IAPP sequence are seen
hydrophobic and amphipathic segment of IAPP, when membrane-bound, would
the membrane are distributed within the N-terminus of hIAPP, with none being
Fig. 2. The aggregation of IAPP in solution (A) and in the presence of membranes (B). (A) In solution IAPP is predominantly unstructured. Aggregation in the absence
of membranes is a multi-step process that proceeds via several different β-sheet containing oligomers and, ultimately, leads to the formation of mature fibrils. (B) The
interaction of soluble, monomeric IAPP with negatively charged membranes results in the formation of α-helical secondary structure as schematically indicated by the
black cylinders. While about 50% (or 15–20 residues) of the peptides becomes helical, the remainder of the peptide stays unstructured. The membrane-bound helical
conformation aggregates to form mature fibrils on a much shorter time scale than the aggregation of IAPP in solution. Significant driving force for aggregation of the
membrane bound peptide is expected from the formation of secondary structure from residues that remain unstructured in the membrane environment. Membrane-
perturbing structures are thought to be formed from oligomers that are either formed in solution or through membrane interaction.
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that results from the essentially two-dimensional diffusion [58].
Although it is still not known which regions of membrane-
bound hIAPP become structured, sequence analysis provides
some hints as to where the helical structure might be induced.
IAPP belongs to the same peptide superfamily as calcitonin and
the calcitonin gene-related peptide [68], for which NMR data
were obtained in the presence of SDS-micelles [69] or water/
trifluoroethanol [70]. Based upon these data, one could expect
that residues ∼8 to 18 in hIAPP might be in a helical
conformation [58] (Fig. 1). Helical structure in this region is
also supported by analysis of amphipathicity as well as helical
propensity [58] (Fig. 1), although it also predicts that the helical
structure could extend even further on the C-terminal end. If
these structural predictions are correct, a significant portion of
the C-terminus, perhaps including some of the most amyloido-
genic regions of the peptide (residues 20–29; [22,71,72], is
likely to be unstructured when in contact with the membrane.
These regions could then readily initiate the aggregation process.
Interestingly, a recent study reported that the helical structures
can bundle up further under conditions of high peptide-to-lipid
ratios [57]. Once in this state, the unfolded region might come
into direct contact and initiate oligomerization [57].
Of interest is the finding that, although rat IAPP (rIAPP) was
able to take up an α-helical, membrane-bound conformation
similar to that of hIAPP, it did not proceed to generate the
formation of β-sheet oligomers and fibrils. Overall, the α-
helicity of membrane-bound rIAPP was found to be about 40%using POPS [58] and about 49–59% using DOPG [57]. These
observations suggest that regions which are homologous in rat
and human IAPP (i.e. excluding residues 25 to 29; Fig. 1)
mediate the formation of α-helical structure. The inability of
rIAPP to form β-sheet aggregates may be due to the presence of
three proline residues within the C-terminal region of the
peptide and their tendency to disrupt secondary structure.
2.2. Permeabilization of lipid membranes by IAPP
2.2.1. Membrane interaction and toxicity of IAPP
The first experimental support for the idea that hIAPP can
permeabilize membranes came forth in 1996, when Mirzabekov
and colleagues [73] showed that hIAPP gave rise to significant
ion fluxes across lipid bilayer membranes. Since that time, a
number of studies have confirmed these findings [17,59,74–79]
and have provided some indication that alterations in membrane
homeostasis could be an important aspect of hIAPP toxicity in
T2DM: (1) while all pertinent studies find that hIAPP can
permeabilize membranes, the non-amyloidogenic and non-toxic
rIAPP was found to have either no activity [17,73] or strongly
reduced activity [57,79]. (2) Application of hIAPP (as well as
that of other amyloidogenic peptides) to GT1–7 cells has been
shown to cause significant rises in cytosolic Ca2+ levels [75].
This effect is thought to be directly due to the membrane
permeabilizing ability of hIAPP and one of the mechanisms by
which hIAPP causes toxicity. (3) Several studies have shown
that membrane perturbation is caused by non-fibrillar forms of
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was found that hIAPP preparations containing these highly
membrane-active, non-fibrillar structures also exhibited the
highest levels of toxicity [17]. (4) The presence of small
intracellular aggregates of hIAPP is associated with significant
membrane abnormalities in islet cells [23]. Collectively, these
data show that hIAPP has a permeabilizing effect on cellular or
synthetic membranes, and that highly membrane-active forms
of hIAPP also exhibit the most pronounced toxicity. Thus, it is
possible that hIAPP membrane interaction could contribute to
the pathogenesis of T2DM.
While there is good agreement that hIAPP can have
deleterious effects on membranes, the precise molecular
mechanisms that confer hIAPP with such activity are not as
clearly understood. Below, we will review different models that
have been put forth to explain the effect of hIAPP onmembranes.
2.2.2. Pores and channels versus a detergent-like effect of
IAPP
Evidence has been presented to support the idea that hIAPP
permeabilizes membranes either through the action of specific
channels (pores) or through a less specific, detergent-like
permeabilization of lipid membranes. While interpreting the
details of these seemingly mutually exclusive models, it is
important to note that most studies have been performed under
experimental conditions that differed somewhat with respect to
lipid composition, buffer solutions, and preparation of hIAPP
(potentially giving rise to varying oligomeric states). Thus, it
might be possible that hIAPP can affect membrane homeostasis
in a variety of ways. Such a case would not be without
precedent. Studies on membrane-lytic host-defense peptides
have shown that, depending on conditions, these peptides can
permeabilize membranes in two ways: In the first, known as the
‘barrel-stave model’, the peptides aggregate to form transmem-
brane pores. In the second, known as the ‘detergent-like’ or
‘carpet‘ model, surface-associated peptides form membrane-
disruptive micelle-like structures that contain both peptides and
lipids [80]. Host defense peptides, such as melittin and
defensins, have been shown to act through both a ‘pore-like’
mechanism and a ‘detergent-like’ mechanism, with the mode of
action determined by lipid composition [81–84].
The formation of an hIAPP channel or transmembrane pore
has been observed in a number of studies [53,73–75].
Mirzabekov et al. observed stable channels in electrical
recordings of planar lipid bilayers. In these studies, an increase
in the negative charge density of the lipids gave rise to increased
channel activity. This observation is consistent with an
electrostatic attraction between the peptide and the lipid bilayer.
hIAPP channels showed poor ion selectivity, as indicated by
their permeability to Na, K, Ca, and Cl ions. Lansbury and
colleagues also observed that hIAPP permeabilized lipid
vesicles in a pore-like mechanism, with the pore allowing
passage of calcium but not larger molecules [76]. By correlating
hIAPP fibrillization to membrane permeability, the authors
concluded that pore formation is caused by an oligomeric, non-
fibrillar form, since membrane permeability increased during
the initial stages of fibrillization but disappeared when maturefibrils began to form. Based upon light-scattering measure-
ments, it was suggested that the active species is an aggregate
comprised of between 20 and 40 hIAPP monomers. In other
studies, a very similar correlation was also observed between
membrane permeabilizing ability and aging of hIAPP in
solution [17,77].
At present, little is known about the structures that mediate
the channel or pore activity of hIAPP. This is an intrinsically
difficult problem that is exacerbated by the often heterogeneous
nature of hIAPP oligomers. Ideally, one would have to be able to
determine both the conductance and structure of a single pore
simultaneously. The study by Quist et al. perhaps comes closest
to this goal by showing that hIAPP exhibits channel-like
behavior in planar bilayers, and that, at least in a subset of
structures, channel-like structures of hIAPP could be observed
by atomic force microscopy (AFM) [74]. These AFM images
indicate that the hIAPP pore is composed of five subunits,
although the structure of the individual subunits was not
resolved. Overall, this pore-like structure of hIAPP is reminis-
cent of the membrane-associated annular pore-like structures
observed for α-synuclein [85–87] and Aβ [88] (for review see
[56]). Consistent with this channel or pore hypothesis, neutron
diffraction has shown that hIAPP (but not rIAPP) adopts in a
trans-bilayer orientation, at least in preparations made by co-
dissolving the peptide with lipid [89].
Kayed and colleagues found that highly enriched preparations
of β-sheet-containing, predominantly spherical hIAPP oligomers
have a membrane permeabilizing effect on planar lipid bilayers
[90]. The notion that oligomers are responsible for toxicity was
further supported by the finding that a conformationally specific
anti-oligomer antibody reversed the changes in hIAPP-depen-
dent conductance. This study, however, found no evidence of
discrete channel or pore formation by hIAPP [90], and identical
results were obtained for other amyloidogenic peptides. Thus, it
appears that hIAPP oligomers do not exclusively permeabilize
membranes by a pore or channel-like mechanism.
Membrane damage by a mechanism other than the formation
of channel or pore-like structures has also been supported by a
number of studies. Based on time-lapse AFM data obtained
using supported lipid bilayers treated with IAPP, Green and
colleagues have suggested that hIAPP-induced membrane
disruption does not occur via the formation of defined pores
[79]. Rather, it was observed that IAPP induced the formation of
small defects on the lipid surface. The defects were found to be
small in size, stable, and able to spread over the entire lipid
surface. The authors suggest that membrane disruption by
hIAPP could be due to loss of lipid from the membrane in a
manner similar to membrane disruption by surfactants such as
Triton X-100. In line with these observations, Sparr et al. found
that aggregation of hIAPP in the presence of membranes
involves the extraction of lipids from the bilayer, leading to
disruption of the bilayer barrier function and membrane leakage
[59]. Extraction of lipids may be a common feature of amyloid
formation in vivo, since extracellular amyloid deposits from a
number of diseases have been found to be associated with
cellular lipids [91]. Finally, in their study of hIAPP induced
membrane disruption Harroun et. al. did not observe well-
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cause membrane disruption may not have a defined structure
[78].
In addition to the β-sheet-containing, predominantly spherical
hIAPP oligomers studied by Kayed et al., it was recently shown
that soluble hIAPP monomers can bind to membranes and
subsequently cause membrane permeabilization [57]. Both rat
and human IAPP exhibited this reactivity, although much more
rIAPP was needed to cause the same amount of vesicle leakage as
the human version. In agreement with the ability of rIAPP to
cause membrane damage, the rat peptide has been shown, using
AFM, to induce membrane defects [79], as well as to insert into
monolayers [92]. For both hIAPP and rIAPP, leakage of vesicle
contents was observed to occur well within the lag time of IAPP
fiber formation, when, according to CD spectroscopy, hIAPP was
still largely in an α-helical conformation [57]. Although the
precise mechanism that causes membrane permeabilization under
these conditions is still unknown, the data suggest that the α-
helical conformation of membrane-bound IAPP could have
membrane-disrupting properties.
In summary, a growing body of evidence suggests that IAPP
plays an important role in the pathogenesis of T2DM, and that
IAPP membrane interaction could be an important mediator of
this toxicity. It has been clearly established that membranes can
play a dual role: both as a generator and as a target of potentially
toxic species of IAPP. However, we have only begun to
understand the underlying mechanisms responsible for these
phenomena. It appears important for both of these questions to
be addressed together, and it is important to keep in mind that
membranes can readily change the structure of IAPP. Therefore,
one cannot necessarily assume that IAPP will retain the
structure of the monomeric or oligomeric state that it was in
when added to the membranes. Ultimately, a structural and
mechanistic understanding of IAPP–membrane interactions
might provide more than just a molecular understanding of
IAPP pathogenesis; it may also assist in formulating avenues by
which to prevent the toxic effects of IAPP.
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